Lundbeck's anti-drinking med Selincro nabs final U.K. funding; Endo pays $25 million-plus for testosterone gel Natesto;

> The U.K.'s cost-effectiveness gatekeepers gave their final OK for Lundbeck's anti-alcoholism drug Selincro (nalmefene). Report

> Fingerpaint, a Saratoga Springs, NY-based agency, snapped up a Phoenix-based shop, Olson Communications, in a bid to build out a West Coast presence to attract more pharma clients based there. Report

> Leo Pharma recruited Barbara Osborne to head up its U.S. regional office as president and CEO; she'll also join the Denmark-based company's global executive team. Release

> Endo Pharmaceuticals ($ENDP) snapped up the rights to a testosterone nasal gel, Natesto, from Trimel BioPharma; the drug was approved by the FDA in May. Release

> Novartis ($NVS) regained its online domain name in Indonesia from a local squatter that was using the domain illegally. Report

> Ireland will require pharma companies to disclose payments to doctors and other healthcare professionals beginning Jan. 1; gifts were banned earlier this year. Report

And Finally... Novartis said the FDA has extended its review of the company's new multiple myeloma drug bortezomib. Release

Suggested Articles

A small group of physicians expressed little interest in new MS drugs from Novartis, Merck KGaA and Biogen but favored a repurposed therapy.

Sanofi and Regeneron recently debuted an unbranded awareness and education campaign around type 2 inflammation and its connections across conditions.

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.